BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Böttger R, Pauli G, Chao PH, Al Fayez N, Hohenwarter L, Li SD. Lipid-based nanoparticle technologies for liver targeting. Adv Drug Deliv Rev 2020;154-155:79-101. [PMID: 32574575 DOI: 10.1016/j.addr.2020.06.017] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Huang Z, Wang H, Chun C, Li X, Xu S, Zhao Y. Self-assembled FGF21 nanoparticles alleviate drug-induced acute liver injury. Front Pharmacol 2023;13. [DOI: 10.3389/fphar.2022.1084799] [Reference Citation Analysis]
2 Foo W, Cseresnyés Z, Rössel C, Teng Y, Ramoji A, Chi M, Hauswald W, Huschke S, Hoeppener S, Popp J, Schacher FH, Sierka M, Figge MT, Press AT, Bauer M. Tuning the corona-core ratio of polyplex micelles for selective oligonucleotide delivery to hepatocytes or hepatic immune cells. Biomaterials 2023. [DOI: 10.1016/j.biomaterials.2023.122016] [Reference Citation Analysis]
3 Fatima M, Karwasra R, Almalki WH, Sahebkar A, Kesharwani P. Galactose engineered nanocarriers: Hopes and hypes in cancer therapy. European Polymer Journal 2022. [DOI: 10.1016/j.eurpolymj.2022.111759] [Reference Citation Analysis]
4 Cheng SH, Groseclose MR, Mininger C, Bergstrom M, Zhang L, Lenhard SC, Skedzielewski T, Kelley ZD, Comroe D, Hong H, Cui H, Hoover JL, Rittenhouse S, Castellino S, Jucker BM, Alsaid H. Multimodal imaging distribution assessment of a liposomal antibiotic in an infectious disease model. J Control Release 2022;352:199-210. [PMID: 36084816 DOI: 10.1016/j.jconrel.2022.08.061] [Reference Citation Analysis]
5 do Nascimento T, de Abreu Garófalo D, de Souza Bustamante Monteiro MS, Santos-oliveira R, dos Santos Matos AP, Ricci-júnior E. Drug Encapsulation: Review of Niosomes for Promoting Antimicrobial Activity. J Nanopart Res 2022;24:262. [DOI: 10.1007/s11051-022-05637-7] [Reference Citation Analysis]
6 Zhang J, Chen J. Circular mRNAs: More stable RNAs lead to more persistent protein expression. Molecular Therapy - Nucleic Acids 2022;30:357-358. [DOI: 10.1016/j.omtn.2022.10.014] [Reference Citation Analysis]
7 Luo F, Yu Y, Li M, Chen Y, Zhang P, Xiao C, Lv G. Polymeric nanomedicines for the treatment of hepatic diseases. J Nanobiotechnol 2022;20:488. [DOI: 10.1186/s12951-022-01708-y] [Reference Citation Analysis]
8 Sommonte F, Weaver E, Mathew E, Denora N, Lamprou DA. In-House Innovative "Diamond Shaped" 3D Printed Microfluidic Devices for Lysozyme-Loaded Liposomes. Pharmaceutics 2022;14. [PMID: 36432675 DOI: 10.3390/pharmaceutics14112484] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Jacobs E, Qian K, Pietsch VL, Richter M, Jones DS, Andrews GP, Tian Y. Design and scale-up of amorphous drug nanoparticles production via a one-step anhydrous continuous process. International Journal of Pharmaceutics 2022;628:122304. [DOI: 10.1016/j.ijpharm.2022.122304] [Reference Citation Analysis]
10 Al Fayez N, Böttger R, Brown J, Rouhollahi E, Li S. The mechanism of Hepatocyte-Targeting and safety profile of Phospholipid-Free small unilamellar vesicles. International Journal of Pharmaceutics 2022;628:122269. [DOI: 10.1016/j.ijpharm.2022.122269] [Reference Citation Analysis]
11 Chaudhuri A, Kumar DN, Shaik RA, Eid BG, Abdel-Naim AB, Md S, Ahmad A, Agrawal AK. Lipid-Based Nanoparticles as a Pivotal Delivery Approach in Triple Negative Breast Cancer (TNBC) Therapy. Int J Mol Sci 2022;23:10068. [PMID: 36077466 DOI: 10.3390/ijms231710068] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Shi Y, Liu Y, Wang S, Huang J, Luo Z, Jiang M, Lu Y, Lin Q, Liu H, Cheng N, You J. Endoplasmic reticulum-targeted inhibition of CYP2E1 with vitamin E nanoemulsions alleviates hepatocyte oxidative stress and reverses alcoholic liver disease. Biomaterials 2022. [DOI: 10.1016/j.biomaterials.2022.121720] [Reference Citation Analysis]
13 Wang X, Li C, Wang Y, Chen H, Zhang X, Luo C, Zhou W, Li L, Teng L, Yu H, Wang J. Smart drug delivery systems for precise cancer therapy. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.08.013] [Reference Citation Analysis]
14 Chen B, Chen Y, Li J, Wang C, Song W, Wen Y, Lin J, Wu Y, Ying T, Zheng C. A Single Dose of Anti-HBsAg Antibody-Encoding mRNA-LNPs Suppressed HBsAg Expression: a Potential Cure of Chronic Hepatitis B Virus Infection. mBio. [DOI: 10.1128/mbio.01612-22] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Xie P, Peng Y, Qiu L. Responsive oligochitosan nano-vesicles with ursodeoxycholic acid and exenatide for NAFLD synergistic therapy via SIRT1. Carbohydrate Polymers 2022;288:119388. [DOI: 10.1016/j.carbpol.2022.119388] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zagkou S, Marais V, Zeghoudi N, Guillou EL, Eskelinen E, Panasyuk G, Verrier B, Primard C. Design and Evaluation of Autophagy-Inducing Particles for the Treatment of Abnormal Lipid Accumulation. Pharmaceutics 2022;14:1379. [DOI: 10.3390/pharmaceutics14071379] [Reference Citation Analysis]
17 Zhou X, Yi L, Lang H, Zhang J, Zhang Q, Yu L, Zhu J, Mi M. Dihydromyricetin-Encapsulated Liposomes Inhibit Exhaustive Exercise-Induced Liver Inflammation by Orchestrating M1/M2 Macrophage Polarization. Front Pharmacol 2022;13:887263. [PMID: 35721117 DOI: 10.3389/fphar.2022.887263] [Reference Citation Analysis]
18 Chen T, Tam N, Mao Y, Sun C, Wang Z, Hou Y, Xia W, Yu J, Wu L. A multi-hit therapeutic nanoplatform for hepatocellular carcinoma: Dual stimuli-responsive drug release, dual-modal imaging, and in situ oxygen supply to enhance synergistic therapy. Materials Today Bio 2022. [DOI: 10.1016/j.mtbio.2022.100338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Benne N, Ter Braake D, Stoppelenburg AJ, Broere F. Nanoparticles for Inducing Antigen-Specific T Cell Tolerance in Autoimmune Diseases. Front Immunol 2022;13:864403. [PMID: 35392079 DOI: 10.3389/fimmu.2022.864403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Liu M, Huang Q, Zhu Y, Chen L, Li Y, Gong Z, Ai K. Harnessing reactive oxygen/nitrogen species and inflammation: Nanodrugs for liver injury. Materials Today Bio 2022. [DOI: 10.1016/j.mtbio.2022.100215] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
21 Kumar M, Jha A, Bharti K, Mishra B. Nanovesicles for hepatic-targeted drug delivery. Applications of Nanovesicular Drug Delivery 2022. [DOI: 10.1016/b978-0-323-91865-7.00015-8] [Reference Citation Analysis]
22 Bindra HS, Singh B. Nanomedicine and Healthcare Systems. Innovative Approaches for Nanobiotechnology in Healthcare Systems 2022. [DOI: 10.4018/978-1-7998-8251-0.ch001] [Reference Citation Analysis]
23 El Awdan SA, F. Asaad G. Liver Fibrosis: Underlying Mechanisms and Innovative Therapeutic Approach. A Review Article. Biomed Pharmacol J 2021;14:1841-1862. [DOI: 10.13005/bpj/2283] [Reference Citation Analysis]
24 Wei X, Yang D, Xing Z, Zhao C, Wang L, Fan Y, Nie H, Liu H. Quercetin loaded liposomes modified with galactosylated chitosan prevent LPS/D-GalN induced acute liver injury. Mater Sci Eng C Mater Biol Appl 2021;131:112527. [PMID: 34857306 DOI: 10.1016/j.msec.2021.112527] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Kong H, Ju E, Yi K, Xu W, Lao YH, Cheng D, Zhang Q, Tao Y, Li M, Ding J. Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma. Adv Sci (Weinh) 2021;8:e2102051. [PMID: 34665528 DOI: 10.1002/advs.202102051] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
26 Moosavian SA, Sathyapalan T, Jamialahmadi T, Sahebkar A. The Emerging Role of Nanomedicine in the Management of Nonalcoholic Fatty Liver Disease: A State-of-the-Art Review. Bioinorg Chem Appl 2021;2021:4041415. [PMID: 34659388 DOI: 10.1155/2021/4041415] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
27 El-Nabarawi M, Nafady M, Elmenshawe S, Elkarmalawy M, Teaima M. Liver Targeting of Daclatasvir via Tailoring Sterically Stabilized Bilosomes: Fabrication, Comparative In Vitro/In Vivo Appraisal and Biodistribution Studies. Int J Nanomedicine 2021;16:6413-26. [PMID: 34556987 DOI: 10.2147/IJN.S319255] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Wang Q, Wei S, Li L, Bu Q, Zhou H, Su W, Liu Z, Wang M, Lu L. miR-139-5p sponged by LncRNA NEAT1 regulates liver fibrosis via targeting β-catenin/SOX9/TGF-β1 pathway. Cell Death Discov 2021;7:243. [PMID: 34531378 DOI: 10.1038/s41420-021-00632-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
29 Zou D, Wang H, Liu X, Xu ZP, Roberts MS, Zhao CX. Artificial cells for the treatment of liver diseases. Acta Biomater 2021;130:98-114. [PMID: 34126265 DOI: 10.1016/j.actbio.2021.06.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Behr M, Zhou J, Xu B, Zhang H. In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges. Acta Pharm Sin B 2021;11:2150-71. [PMID: 34522582 DOI: 10.1016/j.apsb.2021.05.020] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 14.5] [Reference Citation Analysis]
31 Wang Y, Shahi PK, Wang X, Xie R, Zhao Y, Wu M, Roge S, Pattnaik BR, Gong S. In vivo targeted delivery of nucleic acids and CRISPR genome editors enabled by GSH-responsive silica nanoparticles. J Control Release 2021;336:296-309. [PMID: 34174352 DOI: 10.1016/j.jconrel.2021.06.030] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
32 Nguyen A, Böttger R, Li SD. Recent trends in bioresponsive linker technologies of Prodrug-Based Self-Assembling nanomaterials. Biomaterials 2021;275:120955. [PMID: 34130143 DOI: 10.1016/j.biomaterials.2021.120955] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
33 Salunkhe SA, Chitkara D, Mahato RI, Mittal A. Lipid based nanocarriers for effective drug delivery and treatment of diabetes associated liver fibrosis. Adv Drug Deliv Rev 2021;173:394-415. [PMID: 33831474 DOI: 10.1016/j.addr.2021.04.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
34 Vogler J, Böttger R, Al Fayez N, Zhang W, Qin Z, Hohenwarter L, Chao PH, Rouhollahi E, Bilal N, Chen N, Lee B, Chen C, Wilkinson B, Kieffer TJ, Kulkarni JA, Cullis PR, Witzigmann D, Li SD. Altering the intra-liver distribution of phospholipid-free small unilamellar vesicles using temperature-dependent size-tunability. J Control Release 2021;333:151-61. [PMID: 33771624 DOI: 10.1016/j.jconrel.2021.03.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
35 Thi TTH, Suys EJA, Lee JS, Nguyen DH, Park KD, Truong NP. Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines. Vaccines (Basel) 2021;9:359. [PMID: 33918072 DOI: 10.3390/vaccines9040359] [Cited by in Crossref: 97] [Cited by in F6Publishing: 102] [Article Influence: 48.5] [Reference Citation Analysis]
36 Luo J, Zhang Z, Zeng Y, Dong Y, Ma L. Co-encapsulation of collagenase type I and silibinin in chondroitin sulfate coated multilayered nanoparticles for targeted treatment of liver fibrosis. Carbohydr Polym 2021;263:117964. [PMID: 33858569 DOI: 10.1016/j.carbpol.2021.117964] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
37 Taneja P, Sharma S, Sinha VB, Yadav AK. Advancement of nanoscience in development of conjugated drugs for enhanced disease prevention. Life Sci 2021;268:118859. [PMID: 33358907 DOI: 10.1016/j.lfs.2020.118859] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
38 Swarupananda M, Ayon D, Dipanjana A. Lipid nanoparticulate drug delivery system for the treatment of hepatic fibrosis. Arch Hepat Res 2021. [DOI: 10.17352/ahr.000028] [Reference Citation Analysis]
39 Fumoto S, Yamamoto T, Okami K, Maemura Y, Terada C, Yamayoshi A, Nishida K. Understanding In Vivo Fate of Nucleic Acid and Gene Medicines for the Rational Design of Drugs. Pharmaceutics 2021;13:159. [PMID: 33530309 DOI: 10.3390/pharmaceutics13020159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
40 Bai X, Su G, Zhai S. Recent Advances in Nanomedicine for the Diagnosis and Therapy of Liver Fibrosis. Nanomaterials (Basel) 2020;10:E1945. [PMID: 33003520 DOI: 10.3390/nano10101945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]